Propolis, which has been used widely in folk medicine, has been shown to exhibit various biological activities but its immunoregulatory and anti-inflammatory activities in intact animals have not been well studied. We investigated these activities of propolis using an ovalbumin-induced asthma animal model. Mice were immunized and sensitized by exposure to ovalbumin (OVA) antigen and administered with low- (65 mg/kg body weight) and high-dose (325 mg/kg body weight) propolis water extracts by tube feeding. The serum OVA-specific IgE titer and cytokine profiles in cultured splenocytes and bronchoalveolar lavage fluids (BALF) were analyzed. The number of eosinophils in BALF was counted. Here we demonstrate that propolis extracts can suppress the serum levels of OVA-specific IgE and IgG(1), and airway hyperresponsiveness (AHR) in OVA-sensitized mice. There are no significant differences in the concentration of eotaxin or the number of eosinophils in BALF among the four groups. However, the higher dose of propolis extracts decreases the level of IL-5 in BALF. The splenocytes from mice administered with propolis extracts (low- and high-dose groups) exhibit a strong inhibition of IL-10 secretion and up-regulation of IFN-gamma secretion in splenocytes stimulated with concanavalin A (ConA). In addition, cytokine (IFN-gamma, IL-6, and IL-10) secretion in OVA-stimulated splenocytes from the propolis groups was significantly lower than that in the control group. These results suggest that propolis extracts may be a potential novel therapeutic agent for asthma.
"It was also believed to contribute to the anti-inflammatory activity of propolis by being both a lipoxygenase–cyclooxygenase inhibitor and an antioxidant (Onlen et al., 2007). Sy et al. (2006) investigated the activities of propolis using an OVA-induced asthma animal model. Mice were immunized and sensitized by exposure to ovalbumin (OVA) antigen and administered with low (65 mg/kg body weight) and high-dose (325 mg/kg body weight) propolis water extracts by tube feeding. "
"Both treatment with PHE (50 and 200 mg/Kg) reversed the pattern of inflammatory cells in the lung and decreasing the influx of polymorphonuclear inflammatory cells to parenchyma, reversing the pattern of inflammatory cells in the lung and decreasing the influx of polymorphonuclear inflammatory cells to parenchyma. Similarly, it was shown that propolis-treated mice had a reduction in the number of inflammatory cells in the peritoneal bronchoalveolar regions compared with the untreated group . This result is also in accordance with a previous study, which showed that the addition of propolis to the food of asthma patients, as adjunctive therapy in the treatment of this disease, conferred definite advantages by reducing the frequency of crises and the need for rescue medication, possibly improving the patients' immune response . "
[Show abstract][Hide abstract] ABSTRACT: Bee products have been used empirically for centuries, especially for the treatment of respiratory diseases. The present study evaluated the effect of treatment with a propolis hydroalcoholic extract (PHE) produced by Scaptotrigona aff. postica stingless bee in a murine asthma model. BALB/c mice were immunized twice with ovalbumin (OVA) subcutaneously. After 14 days, they were intranasally challenged with OVA. Groups P50 and P200 received PHE by gavage at doses of 50 and 200 mg/kg, respectively. The DEXA group was treated with intraperitoneal injection of dexamethasone. The OVA group received only water. The mice were treated daily for two weeks and then they were immunized a second time with intranasal OVA. The treatment with PHE decreased the cell number in the bronchoalveolar fluid (BAL). Histological analysis showed reduced peribronchovascular inflammation after treatment with PHE especially the infiltration of polymorphonuclear cells. In addition, the concentration of interferon- γ (IFN- γ ) in the serum was decreased. These results were similar to those obtained with dexamethasone. Treatment with S. aff postica propolis reduced the pathology associated with murine asthma due an inhibition of inflammatory cells migration to the alveolar space and the systemic progression of the allergic inflammation.
Evidence-based Complementary and Alternative Medicine 04/2014; 2014(5):951478. DOI:10.1155/2014/951478 · 1.88 Impact Factor
"A single administration of propolis caused no significant effect on both antigen-induced nasal rubbing and sneezing at a dose of 1000 mg/kg, but a significant inhibition was observed after repeated administration for 2 weeks at this dose. Asthma is a chronic inflammatory disorder of the pulmonary airways due to the hyperresponsiveness to inhaled allergens, leading to reversible airflow obstruction and airway inflammation, persistent airway hyperactivity, and airway remodeling . Khayyal et al. (2003) administered an aqueous extract of propolis 13% daily for 2 months to patients with mild-to-moderate asthma. "
[Show abstract][Hide abstract] ABSTRACT: Propolis is a natural resinous mixture produced by honey bees from substances collected from parts of plants, buds, and exudates. Due to its waxy nature and mechanical properties, bees use propolis in the construction and repair of their hives for sealing openings and cracks and smoothing out the internal walls and as a protective barrier against external invaders like snakes, lizards, and so forth, or against weathering threats like wind and rain. Bees gather propolis from different plants, in the temperate climate zone mainly from poplar. Current antimicrobial applications of propolis include formulations for cold syndrome (upper respiratory tract infections, common cold, and flu-like infections), wound healing, treatment of burns, acne, herpes simplex and genitalis, and neurodermatitis. Worldwide propolis has a tremendous popularity, but in India the studies over propolis have just started, not extensively reported except few regions of India like Maharashtra, West Bengal, Tamil Nadu, Gujrat, and Madhya Pradesh.
Advances in Pharmacological Sciences 12/2013; 2013(1):308249. DOI:10.1155/2013/308249
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.